CliffBio
small molecule

DEPOCYT

CYTARABINE

Loss of exclusivity—loss of exclusivity
CompanyPacira Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEPOCYT
Active ingredientCYTARABINE
Strength10MG/ML
Dosage formINJECTABLE, LIPOSOMAL
RouteINJECTION
ModalitySmall molecule
FDA approvalApril 1999
Marketing statusDISCN

More from Pacira Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DEPOCYT patent cliff — loss of exclusivity — | CliffBio